🕒 Last update: loading…

Stock Organogenesis Holdings Inc. ORGO

Organogenesis Holdings Inc. — Investlytic score 1/5 on the five criteria.

-
-
20/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 1/5 criteria met.

  • ❌ Price trend failed
  • ⚠️ Mixed growth
  • ✅ Debt passed
  • ❌ P/E failed
  • ❌ Correction failed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2018 → 2019: -52.61%

Price change 2019 → 2020: 56.55%

Price change 2020 → 2021: 22.71%

Price change 2021 → 2022: -70.89%

Price change 2022 → 2023: 52.04%

Price change 2023 → 2024: -21.76%

Price change 2024 → 2025: 61.87%

Price change 2025 → 2026: -54.25%

Price change 2026 (year to date): -48.92%

Financial growth

Revenue CAGR (8 years): 16.49%

Earnings CAGR (8 years): N/A

Growth status: positive trend (>1%/yr) in revenue, earnings data insufficient/N/A.

Debt

Debt-to-equity ratio: 0.31

Debt/equity < 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: 44.33

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 43.97% from the high over 6 months.

Excessive correction (> 20.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
Organogenesis Holdings Inc.27.10.31–🔒
Onward Medical N.V.–0.25+34.5 %–
Coherus Oncology, Inc.–0.66+26.9 %–
Guerbet S.A.–1.64+5.5 %–
OrganiGram Holdings Inc.2.10.03––

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Key reported figures

Revenue, net income and net margin reported by Organogenesis Holdings Inc. over the latest fiscal years.

Revenue
563 m USD
fiscal year 2025
Net income
37.0 m USD
fiscal year 2025
Net margin
6.6 %
fiscal year 2025
Average annual growth
+10.7 %
Revenue growth over 5 years
Market cap
105 m USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
2020338 m17.2 m5.1 %n/a
2021467 m94.2 m20.2 %+38.2 %
2022451 m15.5 m3.4 %-3.5 %
2023433 m4.9 m1.1 %-3.9 %
2024482 m861,0000.2 %+11.3 %
2025563 m37.0 m6.6 %+16.8 %

Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.

+

Accounts and financial health

Balance sheet and cash flow published by Organogenesis Holdings Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
fragile accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
0.57
risk zone (below 1.81)
Piotroski Score
2 / 9
0 to 3: fragile accounts
Net Debt / EBITDA
-0.78 x
net cash
Fiscal year20212022202320242025
Cash and investments114 m102 m104 m136 m93.7 m
Total Debt132 m124 m119 m43.3 m133 m
Net Debt18.4 m21.3 m15.0 m-92.3 m39.2 m
Equity241 m266 m279 m385 m434 m
Total assets443 m449 m460 m498 m599 m
Operating cash flow62.0 m24.9 m30.9 m14.2 m-10.3 m
Investments (capex)31.2 m33.9 m24.4 m10.0 m14.2 m
Free cash-flow30.8 m-9.0 m6.6 m4.2 m-24.5 m
Share buybacks00025.5 m0
Dividends paid0001.8 m0

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)-0.82 x
Price / book value1.04 x
Return on Equity (ROE)-46.2 %
Return on Invested Capital (ROIC)-24.3 %
Net margin-40.2 %
Debt / equity0.54 x
Current ratio3.32 x
Interest coverage-1,316.15 x
Free cash-flow yield-0.1 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 18/11/2026.

+

Valuation and competitors

Organogenesis Holdings Inc. compared with its sector on the same exchange and with its main competitors.

Company P/E
27.0
29.7 % above the sector
Sector median P/E
20.8
healthcare, Nasdaq
Sector over 10 years
28.2
10-year median, range 20.4 to 45.8

Direct competitors

CompanyMarket cap (USD)P/ENet margin
Organogenesis Holdings Inc.105 m27.16.6 %
SNDL Inc. SNDL346 mn/a-1.7 %
Monopar Therapeutics Inc. MNPR479 mn/a0.0 %
Emergent BioSolutions Inc. EBS311 m4.27.1 %
Evolus, Inc. EOLS449 mn/a-17.4 %
SIGA Technologies, Inc. SIGA223 m11.524.6 %
AngioDynamics, Inc. ANGO493 mn/a-11.6 %
Bicycle Therapeutics plc BCYC253 mn/a-301.7 %
Varex Imaging Corporation VREX783 m19.4-8.3 %
Sector median (Nasdaq)20.8

Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.

+

Analyst consensus and forecasts

What the financial analysts covering Organogenesis Holdings Inc. publish: ratings, price targets and earnings forecasts.

Majority rating
buy
6 analysts

Breakdown of ratings

strong buy 0buy 4hold 2sell 0strong sell 0

Price targets: published for companies listed in the United States only.

Track record against expectations: reported EPS above consensus 3 times over the last 12 releases.

Source: ratings and forecasts published by analysts, collected on 14/11/2026. An analyst rating or target is not a guarantee.

+

Dividends and earnings

Organogenesis Holdings Inc.: dividend history, last distributions, stock splits and earnings releases.

No known dividend for this company.

Earnings releases

DatePublished EPSExpected EPSSurprise
05/11/2026-0.25-0.17n/a
06/08/2026-0.71-0.35n/a
07/05/2026-0.37-0.29n/a
26/02/20260.310.21+44.2 %
06/11/20250.180.21-14.3 %
07/08/2025-0.090.07-228.6 %

Factual data: ex-dividend history and earnings calendar, as of 18/11/2026. A past dividend does not guarantee the next one.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in Organogenesis Holdings Inc.

Free float
47.9 %
share of freely traded shares

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 14/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
Nasdaq
IPO: 05/01/2017
ISIN code
US68621F1021
Workforce
869
full-time employees
Chief executive
Gary S. Gillheeney

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Organogenesis Holdings Inc.

What is the Organogenesis Holdings Inc. share price?

Latest recorded price: 0.810 USD on 13/11/2026, for a market cap of 105 m USD.

What is the revenue of Organogenesis Holdings Inc.?

563 m USD for fiscal year 2025, with net income of 37.0 m USD (net margin 6.6 %).

What do analysts say about Organogenesis Holdings Inc.?

Out of 6 analysts: 4 buy or strong buy, 2 hold, 0 sell or strong sell.

What is the P/E ratio of Organogenesis Holdings Inc.?

Trailing 12-month P/E of 27.0, against 20.8 for the sector median on the same exchange (10-year median: 28.2).

Is Organogenesis Holdings Inc. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US68621F1021).

How many employees does Organogenesis Holdings Inc. have?

869 full-time employees according to the latest published profile.

Who runs Organogenesis Holdings Inc.?

Gary S. Gillheeney is the company's chief executive.

07

Similar stocks